Patient and tumour characteristics of 275 patients
| Characteristic | No. (%)* |
|---|---|
| Age, yr, mean ± SD | 60.8 ± 10.0 |
| Tumour size, mm, mean ± SD, median (range) | 17 ± 13, 15 (0–110) |
| Specimen weight, g, mean ± SD, median (range) | 155 ± 146, 110 (15–1132) |
| Histology | |
| Invasive ductal carcinoma | 237 (86.2) |
| Invasive lobular carcinoma | 15 (5.5) |
| Ductal carcinoma in situ | 18 (6.6) |
| Other invasive (mucinous and papillary) | 3 (1.1) |
| Phyllodes | 2 (0.7) |
| Histologic subtype (invasive, n = 255) | |
| Luminal A | 215 (84.3) |
| ER/PR positive, HER2 positive | 11 (4.3) |
| ER/PR negative, HER2 positive | 7 (2.7) |
| Triple negative | 22 (8.6) |
| SBR grade (invasive, n = 255) | |
| I | 92 (36.1) |
| II | 102 (40.0) |
| III | 52 (20.4) |
| Missing | 9 (3.5) |
| Pathologic T stage (invasive, n = 255) | |
| pT1 | 168 (65.9) |
| pT2 | 81 (31.8) |
| pT3 | 4 (1.5) |
| pT4 | 2 (0.8) |
| Overall TMN stage (invasive, n = 255) | |
| I | 140 (54.9) |
| II | 105 (41.2) |
| III | 10 (3.9) |
| Nodal status (invasive, n = 255) | |
| Negative | 175 (68.6) |
| Positive | 67 (26.3) |
| Not assessed | 13 (5.1) |
ER = estrogen receptor; HER2 = human epidermal growth factor receptor 2; PR = progesterone receptor; SBR = Scarff–Bloom–Richardson; SD = standard deviation.
↵* Unless indicated otherwise